A Simple Framework I Use With Patients When Thinking About Long-Term Medications

In clinical practice, I often have conversations with patients who are trying to make thoughtful decisions about long-term therapies. One example came up recently during a visit with a patient whose LDL cholesterol had been significantly elevated. We started a low-dose statin, and his numbers responded very nicely. His LDL dropped into a much safer range.

Even with that improvement, he brought up an important question: What about the long-term side effects of statins?

This is exactly the type of question I like to hear from patients. Anytime someone is considering a long-term medication — or a major lifestyle change — it's important to pause and think carefully about the risk–benefit balance.

Too often, discussions about medications focus only on one side of the equation: the potential side effects. But good decision-making requires looking at both sides.

In this particular case, the patient had read that statins may slightly increase the risk of developing diabetes. That concern is understandable and has been discussed extensively in the medical literature. Several large randomized trials and meta-analyses have shown a modest increase in incident diabetes among individuals taking statins, particularly in those who already have metabolic risk factors such as obesity, impaired fasting glucose, or metabolic syndrome (Sattar et al., Lancet, 2010; Preiss et al., JAMA, 2011).

But that observation only represents half of the equation.

When we make decisions about therapies, we must always compare two things:

• The potential risks of taking the medication
• The potential risks of not treating the underlying condition

In the case of elevated LDL cholesterol, the alternative to treatment is continued exposure of the arterial wall to atherogenic lipoproteins over many years. Decades of epidemiologic data, Mendelian randomization studies, and randomized clinical trials have consistently demonstrated that elevated LDL cholesterol is a primary causal driver of atherosclerotic cardiovascular disease (Ference et al., Eur Heart J, 2017).

In other words, untreated hyperlipidemia carries its own very real long-term risks.

When statins are studied in large clinical trials, the cardiovascular benefit is substantial. Reductions in myocardial infarction, stroke, and cardiovascular mortality generally outweigh the relatively small increase in diabetes risk observed in susceptible individuals. The Cholesterol Treatment Trialists' Collaboration has shown that for every 1 mmol/L (≈39 mg/dL) reduction in LDL cholesterol, there is roughly a 20–25% reduction in major vascular events (CTT Collaboration, Lancet, 2010).

Seen through this lens, the decision becomes clearer.

The discussion shifts from "Are statins safe?" to a more useful question:

Which option carries the lower long-term risk for this particular patient?

This way of thinking applies to far more than cholesterol management. It is a framework that can be used whenever we make decisions about health interventions. Examples include:

• Starting a medication
• Adopting a new dietary strategy
• Beginning an exercise program
• Taking supplements
• Making meaningful lifestyle changes

Every intervention carries potential risks. But doing nothing often carries risks as well.

Good medical decision-making requires stepping back and looking at the entire picture. When patients and physicians take the time to evaluate both sides of the equation — the benefits and the potential downsides — we can make decisions that are thoughtful, individualized, and grounded in evidence.